PIONEERING CELLULAR IMMUNOTHERAPY

PROVIDING CELL THERAPY PRODUCTS FOR RARE & ACUTE DISEASES 

ABOUT US

MedXCell NKar is a French Life Science company active in the field of immunotherapy. It is specialized in the development of therapeutic solutions combining Natural Killer (NK) cells and monoclonal antibodies. MedXCell NKar is a subsidiary of MedXCell, a Swiss Life Science group. MedXCell NKar’s ambition is to become the leader in providing cell-therapy products for immunotherapy.

ALLOGENEIC

One donor – multiple recipients

BEST IN CLASS

High efficiency – immediate effects

ADAPTATIVE

One pool of cells – multiple products
Specific elimination of pathogenic cells at the origin of different diseases. These cells are targeted by specific modified monoclonal antibodies that guide the ultimate effectors, Natural Killer cells, in their destruction. MedXCell NKar harnesses natural functions of NK cells by directing therapeutic allogeneic NK cells to specific targets that are poorly targeted by endogenous functions in disease states (immune system supplementation).

THERAPEUTIC FOCUS

PIPELINE

MedXCell NKar pipeline comprises an ongoing preclinical proof of concept program (24 months) focused in two hematological cancer.

The next step will address solid cancer and autoimmune cells.

SCIENCE

Natural killer (NK) cells are bone marrow-derived cytotoxic lymphocytes that can destroy target cells without the need for prior antigen stimulation. NK can provide a potential source of allogeneic “off-the-shelf” cellular therapy, mediating significant anti-target effects without inducing potentially lethal side effects.

MedXCell NKar technology, named NKab, allows to stably load NK cells with antibodies targeting specific antigens with no need for any NK cell genetic modifications. Thus, providing antigenic specificity and discrete targeting to innate killer cells. Such technology can lead to a safe, affordable and effective therapy against several diseases and most tumors.

Natural Killer (NK) cells are important cells for the immune system. They are capable of destroying target cells without prior antigen stimulation. MedXCell NKar has a unique technology, named NKab, that “arms” in a stable manner, and without genetic modification, NK cells with an antibody selected to recognize cells specific antigens in troublesome cells NK cells will be produced from umbilical cord blood allowing their allogeneic use. The pool of NK cells produced can serve as a platform on which the most appropriate antibodies is designed and loaded on the NK cells for clearing the target cells. This makes it possible to target a wide range of targets and indications, such as cancers, infectious diseases and  auto-immune diseases.

PARTNERS